Introduction {#S0001}
============

Parkinson's disease with dementia (PDD) refers to dementia during Parkinson's disease (PD), and especially to dementia in the advanced stages of PD. Research shows that 46% of the patients with PD progress to PDD within 10 years of being diagnosed with PD.[@CIT0001],[@CIT0002] PDD seriously reduces patients' quality of life and increases the burden on caregivers, and there are presently fewer methods to treat PDD and treatments are less effective.[@CIT0003]--[@CIT0005] Studies[@CIT0006]--[@CIT0009] have reported that butylphthalide significantly improves cognitive function in patients with vascular cognitive impairment with no dementia, with good safety. In addition, butylphthalide is reported to protect mitochondria, improve energy metabolism in the brain, improve microcirculation, and suppress nerve cell apoptosis. Butylphthalide also increased NR2B and synaptophysin expression in the rat hippocampus after chronic cerebral ischemia, and increased acetylcholine levels in the brain and decreased a reduction in learning and memory in a rat model of stroke. On the other hand, oxiracetam reportedly promotes synthesis of phosphorylcholine and phosphoethanolamine, promotes brain metabolism, improves memory, and reduces intellectual decline.[@CIT0010],[@CIT0011] Finally, research[@CIT0012]--[@CIT0015] has shown that Ginkgo biloba extract (EGb761) can relieve symptoms in a rat model of PD, improve learning and memory ability in a rat model of dementia, and continuously improve cognitive function in patients with mild cognitive impairment in Parkinson's disease (PD-MCI) over six months.

Donepezil is one of the cholinesterase inhibitors. According to the Diagnosis and Treatment Guidelines for PDD formulated by PD and Movement Disorders Group, and neuropsychology and behavioral neurology group of the Chinese Medical Association-Neurology Branch in 2011, Donepezil is recommended to treat PDD in China[@CIT0003]

Thus, in the current study, a "cocktail therapy", consisting of a combination of dl-3n-butylphthalide soft capsules, oxiracetam capsules, Ginkgo biloba extract tablets, and donepezil hydrochloride tablets, was used to treat patients with PDD, and the efficacy and safety of this treatment were observed.

Patients and methods {#S0002}
====================

 {#S0002-S2001}

The study cohort consisted of 60 patients with PDD who were treated in the Second Hospital of Baoding from January 2011 to October 2016. Patient characteristics were as follows: male: 32 cases, female: 28 cases, age: 60--81 years, mean age: 68.6±9.9 years. The patients were randomly divided into test and control groups according to a random number table. Subjects and their families and caregivers, evaluators, and investigators were blinded to the group status of each patient and the experimental drugs. Characteristics of the test group and control group are shown in [Table 1](#T0001){ref-type="table"}. There was no significant difference between the two groups in any of the recorded characteristics. (all *p\>*0.05). This research was approved by the Ethics Committee of the Second Hospital of Baoding, and written informed consent was obtained from patients and their family members.Table 1Comparison of baseline data between two groupsTest groupControl groupStatistic*p*-valueNumber of patients3030Mean age (year)68.8±8.767.9±9.5*t*=0.383\>0.05Gender, n Male1616*χ*^2^=0.067\>0.05 Female1414Course of disease (year)1.9±0.91.8±0.8*t*=0.455\>0.05Education background, n University32*χ*^2^=0.222\>0.05 Middle school2223 Primary school55Occupation, n Teacher11*χ*^2^=0.026\>0.05 Doctor10 Civil servant32 Driver22 Journalist01 Sales clerk11 Company manager12 Athlete11 Workers1716 Cook12 Farmer22 Patients with drinking history, n2120*χ*^2^=0.077\>0.05 Patients with smoking history, n1819*χ*^2^=0.071\>0.05[^1]

Diagnostic and exclusion criteria for PDD {#S0002-S2002}
-----------------------------------------

### Diagnostic criteria for PDD[@CIT0003]--[@CIT0005] {#S0002-S2002-S3001}

Primary PD was confirmed according to the PD diagnostic criteria of the UK PD Society Brain Bank criteria[@CIT0016] and by the PD diagnostic criteria prepared by PD and dyskinesia groups of the Chinese Medical Association-Neurology Branch.[@CIT0017] Patients needed to have symptoms of hypokinesia and one of: static tremor, myotonia, or posture and gait disturbance. Patients also needed to show sensitivity to levodopa treatment. For a diagnosis of PDD, two further conditions needed to be met: that the cognitive disorder was sufficient to reduce the patient's daily living ability, and that the cognitive disorder was observed at least one year after PD dyskinesia was evident. The presence of the following behavioral symptoms support the diagnosis of PDD: 1) Emotional or personality changes; 2) Visual hallucination; 3) Excessive daytime sleepiness; 4) Various different types of delusions and hallucinations. The diagnosis was made by the investigators for each subject with DSM-IVR criteria. The cognitive disorder was evaluated based on the DSM-IVR, which includes seven fields: Directive force, memory function, speech function, application function, attention, feeling (visual, hearing, and perception), and execution function.

### Exclusion criteria of PDD[@CIT0003]--[@CIT0005] {#S0002-S2002-S3002}

There were five possible reasons to exclude patients, as follows: (1) Dementia was caused by other reasons, such as dementia with Lewy bodies and Alzheimer's disease. Secondary parkinsonism and parkinsonism-plus syndromes were also excluded, as were patients with dementia caused by the following reasons: Systemic disease, drug poisoning, vitamin deficiency, and iatrogenic factors; (2) Disturbance of consciousness, mental diseases, and metabolic diseases; (3) Use of other drugs such as huperzine A, memantine, rivastigmine, piracetam, sedatives, anxiolytics, hypnotics, and cholinergic drugs; (4) Patients who were allergic to celery, oxiracetam, ginkgo leaf, donepezil, or piperidine derivatives; (5) PDD patients with other serious diseases who were expected to be dead within one year.

Randomization and allocation sequence {#S0002-S2003}
-------------------------------------

Participants were enrolled by dementia specialists. According to the diagnostic and exclusion criteria for PDD, 60 patients with PDD were enrolled and then randomly allocated into two groups. Third-party doctors who were not involved in participant enrollment, diagnosis and assessment were responsible for the random grouping and drug delivery. The third-party physicians generated random number sequence using SAS software for the participants with PDD. Then sealed envelopes with the serial number outside, group number and treatment allocations inside were produced, and kept in a locked drawer which was inaccessible to all the researchers. The envelopes were opened sequentially by the third-party physicians after baseline assessments, and participants were assigned to two groups (control group and test group) equally according to the group number printed inside the envelopes. The subjects and their families and caregivers, evaluation personnel, and investigators were blinded to each patient's group status and the distribution of experimental drugs.

Treatment method {#S0002-S2004}
----------------

Both two groups were given general treatment for six months, including oral administration of levodopa and benserazide hydrochloride tablets, and pramipexole dihydrochloride, and regulation of blood pressure, blood sugar, and blood fat. Anti-infection and symptomatic treatment were also given to both groups. The control group received 5 mg of donepezil hydrochloride in tablet form (Eisai China Inc., SFDA Approval No. H20050978) orally, once a day for four weeks, and then the dose was increased to 10 mg once a day, for six months. The test group was treated with the "cocktail therapy", which consisted of 5 mg donepezil hydrochloride in tablet form (Eisai China Inc., SFDA Approval No. H20050978) orally, once a day for four weeks, and then the dose was increased to 10 mg once a day; 0.2 g of dl-3n-butylphthalide in soft capsules (CSPC NBP Pharmaceutical Co., Ltd, approval No.: H20050299) orally, 15 mins before each meal, three times a day; 0.8 g of oxiracetam in capsules (Hunan Jianlang Medicine, batch No.: H20030037) orally, three times a day; 80 mg of Ginkgo biloba extract in tablets (Beaufour Ipsen Industrie, H20030122) orally, three times a day. The course of treatment was six months.

Observation indicators {#S0002-S2005}
----------------------

Patients' cognitive function was evaluated with The Montreal cognitive assessment scale (MoCA),[@CIT0018] while the severity of dementia was evaluated with Clinical Dementia Rating Scale sum of boxes (CDR-SB) and the patients' basic living habits, daily living ability, and changes in personality were evaluated using the Blessed-Roth dementia scale. These evaluations were carried out before the treatment and at three and six months after the treatment.

Observation of adverse events {#S0002-S2006}
-----------------------------

Adverse events over the course of the treatments were monitored. Patients' 4 mL of empty-stomach venous blood was taken before the treatment and at six months after the treatment. Blood urea nitrogen, creatinine, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) were inspected using the oxidation resistance method, and any abnormalities were treated according to their symptoms.

Statistical analysis {#S0002-S2007}
--------------------

Measurement data were described as mean ± standard deviation. The ANOVA with repeated measurement design data was used for assessing changes in multiple follow-up indicators at different time points, and two-sample *t*-test was used for comparison between the groups in the study. Count data were expressed as rates and absolute numbers, and comparisons between groups were calculated using a *χ*^2^ test. Differences were considered statistically significant if *p*\<0.05.

Results {#S0003}
=======

Comparisons of MoCA scores between test and control groups before and after treatment {#S0003-S2001}
-------------------------------------------------------------------------------------

There was no difference in MoCA scores between the test and control groups before treatment (*t*=0.292, *p\>*0.05). However, the MoCA scores of the test group at six months after treatment were significantly increased compared with the control group (*t*=2.539, *p*=0.015); these scores were also higher than those before the treatment and at three months in the test group (*F*=5.047, *p*=0.016). The MoCA scores of the control group at six months were increased compared with before the treatment and at three months, but there was no statistical significance in the difference (*F* =2.943, *p=0.069*) ([Table 2](#T0002){ref-type="table"}).Table 2Comparison of MoCA scores in the test and control groups before and after treatment (mean ± SD)GroupsCasesBefore the treatment3 months after the treatment6 months after the treatmentTest group3016.19±2.1417.28±2.4918.53±2.06Control group3016.37±2.61\
*F* =4.196, *P*=0.035\*\
*F* =5.203, *P*=0.014\*\*\
*F* =4.724, *P*=0.027^\#^16.81±2.1717.08±2.35[^2]

At the different time after treatment, the scores for the different components of MoCA in the test group were significantly increased compared with the control group (*F* =4.311, *P*=0.032), the scores for the different components of MoCA after treatment were significantly increased than before treatment in the test group (*F*=5.719, *P*=0.004). The improvement in visual-spatial ability and executive function (*F*=4.093, *p=*0.037), naming (*F*=4.325, *p=*0.031), attention (*F*=3.597, *p=*0.044), language (*F*=5.528, *p=*0.011)，abstract ability (*F*=3.487, *p=*0.046),delayed memory (*F*=5.241, *p=*0.013) and orientation (*F*=3.4498, *p=*0.045) were more obvious in the test group ([Table 3](#T0003){ref-type="table"}).Table 3Comparison of different components of MoCA in the test and control groups before and after treatment (mean ± SD)Before the treatment3 months after the treatment6 months after the treatmentTest groupControl groupTest groupControl groupTest groupControl groupVisual space and executive function1.03±0.421.04±0.401.21±0.511.09±0.561.34±0.41.15±0.53^○^Naming1.81±0.371.80±0.382.07±0.651.91±0.592.23±0.611.99±0.52^●^Attention2.34±1.562.35±1.532.59±1.282.42±1.342.88±1.352.49±1.27^△^Language0.52±0.280.53±0.250.62±0.250.56±0.270.78±0.310.61±0.28^▲^Abstract ability0.58±0.310.57±0.290.60±0.390.58±0.350.69±0.370.59±0.36^□^Delayed memory2.54±1.222.55±1.252.79±1.532.61±1.483.55±1.412.87±1.52^■^Orientation3.24±1.353.26±1.32\
*F* =4.311\
*F* =5.7193.57±1.44\
*P*=0.032\*\
*P*=0.004\*\*3.38±1.373.86±1.273.45±1.33^▽^[^3]

Comparisons of blessed-roth scores between test and control groups before and after treatment {#S0003-S2002}
---------------------------------------------------------------------------------------------

There was no difference in Blessed-Roth scores between the test and control groups before treatment (*t*=0.128, *p*\>0.05). The Blessed-Roth scores of the test group at six months were significantly decreased compared with the control group (*t*=2.601, *p*=0.013); they were also lower than those before the treatment and at three months in the test group (*F* =3.713, *p*=0.042). The Blessed-Roth scores of the control group at six months were decreased compared with before the treatment and at three months, but there was no statistical significance in the difference (*F*=2.876, *p=*0.074) ([Table 4](#T0004){ref-type="table"}).Table 4Comparison of Blessed-Roth scores in the test and control groups before and after treatment (mean ± SD)GroupsCasesBefore the treatment3 months after the treatment6 months after the treatmentTest group3010.19±2.309.26±2.197.84±2.01Control group3010.27±2.54\
*F* =4.215, *P*=0.034\*\
*F* =5.437, *P*=0.011\*\*\
*F* =4.806, *P*=0.024^\#^9.92±2.029.17±1.95[^4]

Comparisons of CDR-SB scores between test and control groups before and after treatment {#S0003-S2003}
---------------------------------------------------------------------------------------

There was no difference in CDR-SB scores between the test and control groups before treatment (*t*=0.092, *p\>*0.05). The CDR-SB scores of the test group at six months were significantly decreased compared with the control group (*t*=2.421, *p*=0.017); they were also lower than those before the treatment and at three months in the test group (*F*=3.591, *p*=0.045). The CDR-SB scores of the control group at six months were decreased compared with before the treatment and at three months, but there was no statistical significance in the difference (*F*=2.517, *p=*0.083) ([Table 5](#T0005){ref-type="table"}).Table 5Comparison of CDR-SB scores in the test and control groups before and after treatment (mean ± SD)GroupsCasesBefore the treatment3 months after the treatment6 months after the treatmentTest group304.98±1.244.67±1.153.91±0.93Control group304.95±1.29\
*F* =4.189, *P*=0.035\*\
*F* =5.038, *P*=0.015\*\*\
*F* =4.457, *P*=0.03^\#^4.87±1.084.52±1.02[^5]

Safety analysis {#S0003-S2004}
---------------

Before treatment, there was one patient with abnormal liver function in each of the two groups. Over the course of the treatment, patients in the two groups showed stable vital signs, with no adverse events in the digestive system, nervous system, renal function, or with allergies. In the test group, there were four patients with elevated ALT levels and one patient with elevated AST levels; all of them had levels of less than 80 U/L. In the control group, there were two patients with elevated ALT and two patients with elevated AST; both of them had levels of less than 80 U/L. The liver protection therapy (by the administration of vitamins and glucuronolactone) was given and these levels returned to normal. There were no significant differences (*p*\>0.05) between the results of AST and ALT in the test group (16.67%) and those of the control group (13.33%) ([Table 6](#T0006){ref-type="table"}).Table 6Comparison of cases with abnormal liver function in the two groups before treatmentGroupnBefore treatmentAt 6 months after the treatment*χ*^2^*p*-valueTest group3015 (16.67%)0.11\>0.05Control group3014 (13.33%)[^6]

Discussion {#S0004}
==========

PD is a common degenerative disease in the central nervous system, and patients with PD may present with dementia to different degrees. PDD in the later stages can seriously affect a patient's cognitive function and self-care ability, which in turn significantly reduces the patient's quality of life and increases the burden placed on society and the patient's family. This study showed that, before treatment, the MoCA scores of PDD patients were significantly decreased while the Blessed-Roth dementia scale, and CDR-SB scores were significantly increased. These findings were consistent with the results from previous investigations.[@CIT0001],[@CIT0002] In the current study, a "cocktail therapy", consisting of dl-3n-butylphthalide, oxiracetam, Ginkgo biloba extract, and donepezil hydrochloride, was used to treat patients with PDD. The efficacy and safety of this "cocktail therapy" treatment was also observed, and it was found to be safe, which is consistent with previous research.[@CIT0006]

Previous studies[@CIT0019]--[@CIT0022] have shown that the impairment in cognition in PD is related to many factors, including a reduction in brain tissue perfusion, destruction of the cholinergic system, reduction in the brain's metabolic rate, structural impairment of brain tissue, toxicity of excitatory amino acids, and oxidative stress. Winklhofer et al,[@CIT0021],[@CIT0022] found that mitochondrial dysfunction plays a core role in the pathogenesis of PD, and that functional lesions in mitochondria could cause cellular damage, aging, and neurodegenerative disease.

In this study, at six months after treatment with the "cocktail therapy", MoCA scores were obviously improved compared with both pretreatment and control scores. These results show that cognitive function in PPD patients can be improved, and that the degree of dementia can be relieved over time. They also show that our "cocktail therapy" gives better results than treatment with just donepezil hydrochloride. We also showed that "cocktail therapy" treatment resulted in a decrease in both Blessed-Roth and CDR-SB scores compared with pretreatment scores, and that at six months after treatment, scores were also obviously decreased in these patients compared with those in the control group. These results show that the quality of life of the patients with PDD was improved over the course of the therapy, and that our "cocktail therapy" was more effective than treatment with just donepezil hydrochloride. The reason for this improvement with a combination of therapies may be related to the fact that: multiple studies[@CIT0006]--[@CIT0009] have demonstrated that by triggering various pathways, dl-3n-butylphthalide seems to interrupt the development of physiopathological processes that lead to cerebral damage, increase the number of blood capillaries and reconstruct microcirculation in the ischemic region, and improve brain perfusion. Following ischemia, dl-3n-butylphthalide has also been shown to protect mitochondria and improve energy metabolism, suppress the release of glutamic acid and the generation of free radicals, reduce apoptosis, reduce the degree of damage to neurological function, increase the synthesis of acetylcholinesterase, and improve acetylcholine levels in the brain, so that learning and memory functions can improve.

Oxiracetam is a nootropic drug; it can increase the release of acetylcholine by promoting synthesis of phosphorylcholine and phosphorylethanolamine, stimulate specific central nervous pathways through the blood--brain barrier, promote synthesis of triphosadenine, increase the synthesis of proteins and nucleic acids in the brain, and improve the memory and learning of patients with memory and intelligence disturbances.[@CIT0010],[@CIT0011]

The main components of the Gingko biloba extract that was used in this study, EGb761, are total flavonoid glycoside and bilobalide. These components may treat PD-related cognitive disorders through strengthening the brain's oxygen supply, protecting ATP enzymatic activity of the nerve cell, scavenging free radicals and lipid peroxidase, preventing the accumulation of peroxide, suppressing the release of excitatory neurotransmitters, and protecting dopaminergic neurons, among other functions. Moreover, EGb761 can promote the secretion of neurotrophic factors, accelerate repair and proliferation of nerve cells, prevent neuron damage, improve learning and memory in a rat model of dementia, and improve the cognitive function of patients with PD-MCI.[@CIT0012]--[@CIT0015]

[Table 2](#T0002){ref-type="table"} shows that the MoCA scores of the control group at six months were increased compared with before the treatment and at three months, and [Tables 4](#T0004){ref-type="table"} and [5](#T0005){ref-type="table"} show that the Blessed-Roth and CDR-SB scores of the control group at six months were decreased compared with before the treatment and at three months, but all of them were no statistical significance in the difference (*P\>*0.05). However, in the test group, the MoCA scores of PDD patients were increased while the Blessed-Roth dementia scale and CDR-SB scores were decreased at three months, and they were particularly obvious at six months (*P*\<0.05). [Table 3](#T0003){ref-type="table"} shows that the scores for the different components of MoCA in the test group were significantly increased compared with the control group after treatment. Visual-spatial ability, executive function, naming, attention, delayed memory, and orientation had improved more obvious than language and abstraction. This shows that the effect of the "cocktail therapy" was more effective than treatment with just donepezil hydrochloride. The Blessed-Roth dementia scale allows the assessment of social activity ability and self-care ability in daily life, so the improvement in the change of the Blessed-Roth scores in the test group at six months indicates that cocktail therapy seemed to reduce the motor symptoms of PD.

In addition to cognitive impairment, patients with PDD also have a variety of psychobehavioral symptoms, including hallucinations, illusions, delusions, mood changes (such as depression), apathy, REM sleep disorders, among which visual hallucinations and illusions are more common. Mood changes, in particular depression, are also common with dementia. Depression can affect cognitive performance. Patients with PDD who have depression should be given antidepressant treatment before evaluating their cognitive function.[@CIT0023],[@CIT0024] However, the association between mood states and cognitive function in patients with PDD after the treatment need to be further investigated.

[Table 6](#T0006){ref-type="table"} shows that there was no significant difference between the results of AST and ALT in the test group (16.67%) and the control group (13.33%), There were no adverse events in the digestive system, nervous system, renal function, or with allergies. The results indicate that the "cocktail therapy" was safety, which was consistent with the findings of the previous study.[@CIT0006] We considered that this may be related to the following reasons: 1) Some of the side effects in patients with dementia are often poorly recognized, which may look similar to the symptoms of PDD. 2) Virtually all patients with PD need medications, such as levodopa and benserazide hydrochloride to relieve their symptoms,[@CIT0025] and some of the side effects may be similar to those of levodopa and benserazide hydrochloride. 3) There may be a potential mechanism that can counteract any potential adverse effects of the drugs, which need further investigation.

The reason for this improvement with a combination of therapies may be related to the fact that butylphthalide, oxiracetam, and Ginkgo biloba extract can improve microcirculation in the brain, improve the use of glucose and oxygen in brain tissue, promote synthesis of triphosadenine and energy metabolism in brain cells, resist oxidative stress, protect nerve cells, and strengthen learning and memory, among other functions. These effects may be behind the improvement in cognitive function and self-care ability that we observed in patients with PDD following "cocktail therapy".

This research shows that a "cocktail therapy" consisting of dl-3n-butylphthalide, oxiracetam, Ginkgo biloba extract, and donepezil hydrochloride, can be successfully used to treat patients with PDD. This treatment helped to improve patients' symptoms and quality of life, with good safety. However, the sample size in this study is small and the observation time is relatively short; therefore, to verify the accuracy of these results, a trial of this "cocktail therapy" needs to be carried out using a larger sample size, longer time period, and multiple centers.

The authors thank the patients and their families for their participation. The authors also thank the third-party doctors: physician Lan Yu and physician Liu Liu.

Abbreviation list {#S0005}
=================

PDD, Parkinson's disease with dementia; PD, Parkinson's disease; MoCA, Montreal cognitive assessment scale; CDR-SB, Clinical Dementia Rating Scale sum of boxes; AST, aspartate aminotransferase; ALT, alanine aminotransferase; PD-MCI, mild cognitive impairment in Parkinson's disease.
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[^1]: **Notes:***p*\>0.05, comparison of baseline data between two groups. The control group received 10 mg of donepezil hydrochloride tablets orally, once a day. The test group was treated with a "cocktail therapy", which consisted of 10 mg of donepezil hydrochloride tablets taken orally, once a day; 200 mg of dl-3n-butylphthalide soft capsules taken orally, 15 mins before each meal, three times daily; 800 mg of oxiracetam capsules taken orally, three times daily; and 80 mg of Ginkgo biloba extract tablets taken orally, three times daily.

[^2]: **Notes:** \*Indicates post-treatment comparison between two groups; \*\*Indicates different time points before and after treatment for comparisons within the test group; ^\#^Indicates different time points before and after treatment for comparisons between the two groups. The control group received 10 mg of donepezil hydrochloride tablets orally, once a day. The test group was treated with a "cocktail therapy", which consisted of 10 mg of donepezil hydrochloride tablets taken orally, once a day; 200 mg of dl-3n-butylphthalide soft capsules taken orally, 15 mins before each meal, three times daily; 800 mg of oxiracetam capsules taken orally, three times daily; and 80 mg of Ginkgo biloba extract tablets taken orally, three times daily.

[^3]: **Notes:** \*Indicates post-treatment comparison between two groups; \*\*Indicates different time points before and after treatment for comparisons within the test group. The control group received 10 mg of donepezil hydrochloride tablets orally, once a day. The test group was treated with a "cocktail therapy", which consisted of 10 mg of donepezil hydrochloride tablets taken orally, once a day; 200 mg of dl-3n-butylphthalide soft capsules taken orally, 15 mins before each meal, three times daily; 800 mg of oxiracetam capsules taken orally, three times daily; and 80 mg of Ginkgo biloba extract tablets taken orally, three times daily. ^o^*F*=4.093, *p=0.037*. ^●^*F*=4.325, *p=0.031*. ^△^*F* =3.597, *p=0.044*. ^▲^*F*=5.528, *p=0.011*. ^□^*F*=3.487, *p=0.046*. ^■^*F*=5.241, *p=0.013*. ^▽^*F*=3.4498, *p=0.04.*

[^4]: **Notes:** \*Indicates post-treatment comparison between two groups; \*\*Indicates different time points before and after treatment for comparisons within the test group; ^\#^Indicates different time points before and after treatment for comparisons between the two groups. The control group received 10 mg of donepezil hydrochloride tablets orally, once a day. The test group was treated with a "cocktail therapy", which consisted of 10 mg of donepezil hydrochloride tablets taken orally, once a day; 200 mg of dl-3n-butylphthalide soft capsules taken orally, 15 mins before each meal, three times daily; 800 mg of oxiracetam capsules taken orally, three times daily; and 80 mg of Ginkgo biloba extract tablets taken orally, three times daily.

[^5]: **Notes:** \*Indicates post-treatment comparison between two groups; \*\*Indicates different time points before and after treatment for comparisons within the test group; ^\#^Indicates different time points before and after treatment for comparisons between the two groups. The control group received 10 mg of donepezil hydrochloride tablets orally, once a day. The test group was treated with a "cocktail therapy", which consisted of 10 mg of donepezil hydrochloride tablets taken orally, once a day; 200 mg of dl-3n-butylphthalide soft capsules taken orally, 15 mins before each meal, three times daily; 800 mg of oxiracetam capsules taken orally, three times daily; and 80 mg of Ginkgo biloba extract tablets taken orally, three times daily.

[^6]: **Notes:**The control group received 10 mg of donepezil hydrochloride tablets orally, once a day. The test group was treated with a "cocktail therapy", which consisted of 10 mg of donepezil hydrochloride tablets taken orally, once a day; 200 mg of dl-3n-butylphthalide soft capsules taken orally, 15 mins before each meal, three times daily; 800 mg of oxiracetam capsules taken orally, three times daily; and 80 mg of Ginkgo biloba extract tablets taken orally, three times daily.
